Pharmaceuticals Egypt

Egypt CAR-T Cell Therapy Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Egypt CAR-T Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Egypt · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $13.7 Mn Placeholder estimate
Estimate 2025 $17.1 Mn 0.3% of the global market
Projected 2034 $130.3 Mn 661.3% Adds $113.2 Mn over 9 forecast years
CAGR 2025–2034 25.3% Faster than 92% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Egypt is 0.26% of the global market.
  • In Africa, the largest is South Africa at $37.6 Mn.
  • Fastest growing: Egypt (this report) at 25.3% a year.
  • Egypt ranks 2nd of 3 by size in Africa.

Market size projection

Egypt

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$113.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
CAR-T Cell Therapy Market market size by year, Egypt
YearMarket sizeChange that yearSince 2025
2024 (estimate) $13.7 Mn — —
2025 (base) $17.1 Mn +$3.5 Mn —
2026 (forecast) $21.4 Mn +$4.3 Mn +25.3%
2027 (forecast) $26.9 Mn +$5.4 Mn +57%
2028 (forecast) $33.7 Mn +$6.8 Mn +96.7%
2029 (forecast) $42.2 Mn +$8.5 Mn +146.5%
2030 (forecast) $52.9 Mn +$10.7 Mn +208.9%
2031 (forecast) $66.2 Mn +$13.4 Mn +287%
2032 (forecast) $83.0 Mn +$16.8 Mn +384.9%
2033 (forecast) $104.0 Mn +$21.0 Mn +507.6%
2034 (forecast) $130.3 Mn +$26.3 Mn +661.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Egypt CAR-T Cell Therapy Market Analysis at a glance
Market size, 2025$17.1 Mn placeholder estimate
Forecast, 2034$130.3 Mn placeholder estimate
Growth (CAGR), 2025–203425.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersGilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and 1 more (see all)
Regulator in EgyptEDASource: Egyptian Drug Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Egypt CAR-T Cell Therapy Market Analysis Executive Summary

CAR-T cell therapy changes a patient's own immune T cells so they can find and kill cancer cells, mainly in blood cancers.

Key segments of the CAR-T Cell Therapy market include target (CD19, BCMA and Others) and indication (Lymphoma, Leukemia and Multiple Myeloma).

Bar chart: Egypt CAR-T Cell Therapy market size, 2024–2034, placeholder estimates. $13.7 Mn in 2024, $17.1 Mn in 2025 and $130.3 Mn in 2034, 25.3% CAGR.
Egypt CAR-T Cell Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Egypt CAR-T Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the CAR-T Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the CAR-T Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for CAR-T Cell Therapy Market in Egypt

The CAR-T Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for CAR-T Cell Therapy Market in Egypt

CAR-T Cell Therapy in Egypt: rules and payment

Medicines are registered with the Egyptian Drug Authority (EDA), set up in 2019.⁠[1] A universal health insurance system, set up by Law No. 2 of 2018, is being rolled out governorate by governorate, starting with Port Said in 2019.⁠[2]

[1] Egyptian Drug Authority. Checked 14 Nov 2026.

[2] Universal Health Insurance Authority. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for CAR-T Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Egypt.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in CAR-T Cell Therapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

CAR-T Cell Therapy in context

Egypt compared

  • Health spending per person: 141 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.67 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 5.3% of people (2025). World: 10.4% of people (2025). 3rd highest of the 17 countries we cover in Africa.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the CAR-T Cell Therapy market in Egypt?
Placeholder estimate: about $17.1 Mn in 2025, rising to about $130.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the CAR-T Cell Therapy market in Egypt growing?
Placeholder estimate: about 25.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the CAR-T Cell Therapy market report cover?
The report splits the market by target (CD19, BCMA, Others), indication (Lymphoma, Leukemia, Multiple Myeloma, Autoimmune Diseases) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the CAR-T Cell Therapy market?
Key players include Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and Autolus Therapeutics.
What is driving the CAR-T Cell Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.
Who regulates CAR-T Cell Therapy in Egypt?
Medicines are registered with the Egyptian Drug Authority (EDA), set up in 2019. Source: Egyptian Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Egypt?
A universal health insurance system, set up by Law No. 2 of 2018, is being rolled out governorate by governorate, starting with Port Said in 2019. Source: Universal Health Insurance Authority. Checked 14 Nov 2026.
How much research is published on CAR-T Cell Therapy?
PubMed lists 7,618 papers on CAR-T Cell Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Egypt

See all

Related on cell and gene therapy and oncology

See the topic